metaPreg - Valproate (Paternal exposure) during pregnancy

Valproate (Paternal exposure) updated on 03-06-2026

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	0.83 [0.64, 1.06]	0%	3 studies	713	1,646	not evaluable	ROB	-
Major congenital malformations	0.84 [0.64, 1.10]	0%	2 studies	659	1,510	not evaluable	ROB	-
1 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
ASD (Autism spectrum disorder): Diagnosis	1.10 [0.89, 1.35]	0%	5 studies	12,140	6,883	not evaluable	ROB	-
ASD (Autism spectrum disorder): Diagnosis/Risk	1.10 [0.89, 1.35]	0%	5 studies	12,140	6,883	not evaluable	ROB	-
Neuro-developmental disorders (as a whole)	1.11 [0.99, 1.25]	0%	4 studies	1,771	6,496	not evaluable	ROB	-
ADHD (Attention deficit hyperactivity disorder): Diagnosis	1.02 [0.87, 1.20]	2%	5 studies	43,031	6,792	not evaluable	ROB	-
ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk	1.02 [0.87, 1.20]	2%	5 studies	43,031	6,792	not evaluable	ROB	-
Language disorders/delay	1.28 [1.05, 1.57]	15%	3 studies	43,280	4,331	not evaluable	ROB	1.88 [1.27; .]
Cognitive developmental disorders/delay (> 6 years old)	1.35 [0.93, 1.95]	0%	4 studies	4,987	6,488	not evaluable	ROB	-
Severe cognitive developmental delay (Mental retardation) (> 6 years old)	1.35 [0.93, 1.95]	0%	4 studies	4,987	6,488	not evaluable	ROB	-
Learning disorders	1.08 [0.78, 1.49]	0%	2 studies	2,531	4,027	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study